Van Craenenbroeck K, Vanhoenacker P, Haegeman G. Lentiviral vector transduction of NOD/SCID repopulating cells results in multiple vector integrations per transduced cell: risk of insertional mutagenesis. Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Site-specific genomic integration produces therapeutic Factor IX levels in mice. The insulation of genes from external enhancers and silencing chromatin. Transcription start regions in the human genome are favored targets for MLV integration. Retroviral vector integration occurs into preferred genomic targets of human bone marrow repopulating cells. HIV-1 integration in the human genome favors active genes and local hotspots. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. Murine leukemia induced by retroviral gene marking. Side effects of retroviral gene transfer into hematopoietic stem cells. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Gene therapy of RAG-2−/− mice: sustained correction of the immunodeficiency. Self-selection by genetically modified committed lymphocyte precursors reverses the phenotype of JAK3-deficient mice without myeloablation. Mol Ther 2003 7: S448.īunting KD, Lu T, Kelly PF, Sorrentino BP. Correction of the immune and metabolic defect of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Corrective gene transfer into bone marrow CD34+ cells for adenosine deaminase (ADA) deficiency: results in four patients after one year of follow-up. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.

Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates. Persistence and expression of the adenosine deaminase gene for twelve years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. American Society of Gene Therapy's Sixth Annual Meeting Executive Summaries, Vol. Immune Recovery Following Retroviral Mediated Common Gamma Chain Gene Therapy for X-linked Severe Combined Immunodeficiency. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1 ((gamma) c deficiency). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells. A defined window for efficient gene marking of severe combined immunodeficient-repopulating cells using a gibbon ape leukaemia virus-pseudotyped retroviral vector.

Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Nat Rev Immunol 2001 3: 200–208.Ĭavazzana-Calvo M et al. Primary immunodeficiency diseases: an experimental model for molecular medicine.

Gene therapy for scid